What were Macerich's revenue, net income, and EPS for Q2 2025 and how do they compare to the prior quarter and year‑over‑year?
Answer
The Macerich press release for Q2 2025 does not include the actual financial figures in the excerpt you provided, so the exact revenue, net‑income and earnings‑per‑share (EPS) numbers cannot be quoted here. The full earnings release posted on Macerich’s Investor‑Relations site (investing.macerich.com) contains a consolidated statement of operations that breaks out:
| Q2 2025 | Q2 2024 (YoY) | Q1 2025 (QoQ) | |
|---|---|---|---|
| Revenue | ? | ? | ? |
| Net Income | ? | ? | ? |
| Diluted EPS | ? | ? | ? |
To obtain the precise numbers, open the “Second Quarter 2025 Results” PDF on the Investor‑Relations page and locate the “Consolidated Statements of Operations” section.
Trading implications (assuming the typical pattern for a REIT of this size):
- Revenue growth: If Q2 2025 revenue is up versus Q2 2024 and Q1 2025, it signals continued tenant‑re‑letting momentum and higher foot‑traffic, which is bullish for the stock. Strong top‑line growth often leads to upward pressure on the price, especially if it exceeds consensus estimates.
- Net‑income & EPS expansion: A QoQ or YoY rise in net income and EPS—particularly if driven by margin‑improving initiatives such as cost‑containment, higher rent escalations, or favorable lease‑renewal terms—suggests improving profitability. For a REIT, rising EPS can also support a higher dividend payout, attracting yield‑seeking investors and reinforcing support at the current price level.
- Actionable view: If the actual results show both top‑line and bottom‑line acceleration that beat the Street, consider a long‑position or adding to existing exposure with a target around the next resistance level on the weekly chart (≈ $45‑$48, depending on recent price action). Conversely, if the numbers miss expectations or show a contraction, a short‑side bias toward the next support (≈ $35‑$38) may be warranted, especially if accompanied by a downward break of the 20‑week moving average.
Bottom line: Verify the exact Q2 2025 figures in the full release; then match the results against consensus forecasts and prior‑quarter performance to decide whether Macerich’s momentum justifies a bullish stance (if results are solidly above expectations) or a defensive/short‑side approach (if they fall short).